Nucleus basalis injections of N-methyl-D-aspartate enhance memory of rats in the double Y-maze

Inhibitory avoidance memory deficit induced by scopolamine: Interaction of cholinergic and glutamatergic systems in the ventral tegmental area

Interaction of cholinergic and glutamatergic inputs in the ventral tegmental area (VTA) influencing a learned behavior is a topic of great interest. In the present study the effect of intra-VTA administration of a nonselective muscarinic acetylcholine antagonist, scopolamine, and N-methyl-d-aspartate (NMDA) receptor agents by themselves as well as their interactions on consolidation and retrieval of inhibitory avoidance (IA) memory have been investigated. A step-through inhibitory avoidance task was used for memory assessment in male Wistar rats. The results showed that intra-VTA administration of scopolamine (1 and 2microg/rat) and NMDA receptor antagonist, MK-801 (0.75 and 1microg/rat) immediately after training, impaired consolidation of IA memory. Interestingly, co-administration of an ineffective dose of MK-801 (0.5microg/rat) with ineffective doses of scopolamine (0.25 and 0.5microg/rat) significantly decreased the consolidation process. Post-training intra-VTA injections of NMDA (0.001 and 0.01microg/rat) had no effects by itself, whereas its co-administration with scopolamine (2microg/rat) prevented the effect of the later drug. The results also showed that pre-test intra-VTA administration of scopolamine (3 and 4microg/rat) and MK-801 (1 and 2microg/rat) impaired retrieval of the IA memory. Moreover, co-administration of an ineffective dose of MK-801 (0.5microg/rat) with ineffective doses of scopolamine (1 and 2microg/rat) increasingly reduced the retrieval of the IA memory. On the contrary to its post-training treatment, pre-test administration of NMDA either alone or in combination with scopolamine caused no significant effect on retrieval of IA memory. It can be concluded that muscarinic acetylcholine and NMDA glutamate receptors in the VTA are involved in the mechanism(s) underlying consolidation and retrieval of the IA memory.

Chronic administration of a Ginkgo biloba leaf extract facilitates acquisition but not performance of a working memory task

RATIONALE

Ginkgo biloba leaf extracts have been shown to improve learning and memory when administered chronically prior to the learning phase. However, the influence of Ginkgo on learning without prior chronic treatment and on memory per se (i.e., post-training administration) is less clear. Thus, experiment 1 investigated the influence of Ginkgo on acquisition, and experiment 2 examined the acute and chronic effects of Ginkgo on memory in rats using a food-reinforced two-component double Y-maze task.

MATERIALS AND METHODS

In experiment 1, 17 rats were treated daily with a standardized G. biloba extract (13.75 mg/kg, i.p.) or vehicle 30 min prior to daily maze training for 14 days. In experiment 2, 12 rats received 24 training trials daily, then received Ginkgo (0, 0.25, 2.5, 13.75, or 25 mg/kg, i.p.) 30 min prior to each test session. Subsequently, the same rats received daily injections of either Ginkgo (13.75 mg/kg, i.p.) or its vehicle. Memory was tested after 10 and 20 days of drug treatment, once under the influence of the drug and once in a drug-free state.

RESULTS

In experiment 1, Ginkgo-treated rats reached the training criteria significantly faster and made fewer errors. In experiment 2, post-training Ginkgo administration did not enhance memory.

DISCUSSION

Taken together, results demonstrate that repeated daily pre-session Ginkgo injection subtly facilitates acquisition of a spatial working memory task, but neither acute nor chronic post-training exposure enhances spatial working memory. We conclude that ongoing Ginkgo administration does not offer any continued beneficial effects in an already-learned working memory task.

Impaired learning in adulthood following neonatal delta9-THC exposure

Cannabis is one of the most commonly used illicit drugs during pregnancy, but little is known about the lasting effects of early-life exposure to this drug. In this study, male Wistar rat pups were treated daily with (-)-delta9-tetrahydrocannabinol (THC; 5 mg/kg, s.c.) or its vehicle between postnatal days (PND) 4 and 14. Drug administration during this early postnatal period in rats is analogous to the third trimester of gestation in humans, which is a major period of synaptogenesis. Rats were subsequently tested drug-free during young adulthood (PND 56) using a two-component food-motivated double Y-maze test. Each trial included distinct spatial discrimination and delayed alternation components, which permitted the simultaneous assessment of reference memory and working memory. Rats were tested for 30 trials/day, 5 days/week for 5 weeks. Results revealed no significant differences between THC- and vehicle-treated rats in the spatial discrimination task. However, compared to vehicle-treated rats, THC-treated rats committed significantly more errors, and required significantly longer to obtain 80% correct over two consecutive days in the delayed alternation task. Results suggest that neonatal THC exposure leads to a specific and lasting deficit in learning in adulthood, which is likely due to impaired working memory function.

Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats

3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') and cannabis are two of the most commonly used illicit drugs in the western world, and are often used in combination. Very little research has examined their effect on cognitive function or behavior when combined, The present study used a double Y-maze task to examine the acute effect of MDMA and delta9-tetrahydrocannabinol (THC, the principal psychoactive ingredient of cannabis) on mnemonic function in rats, at a range of doses representative of common human use. Experiment I (low doses) examined the effect of 0.25 mg/kg THC and 1.25 mg/kg MDMA alone and together. At these doses MDMA or THC given alone had no effect on working memory, but the co-administered drugs significantly disrupted working memory. Experiment 2 (medium doses) examined the effect of 0.5 mg/kg THC and 2.5 mg/kg MDMA given alone or together. At these doses THC, but not MDMA, impaired working memory. Although MDMA alone had no effect, it exacerbated the impairment due to THC when the drugs were co-administered. Experiment 3 (high doses) examined the effects of 1 mg/kg THC and 5 mg/kg MDMA alone and together. Both drugs significantly impaired memory when given alone, although the impairment due to MDMA was less than that caused by THC. When co-administered at these doses, the drugs caused a major disruption of behavior and this precluded ascribing a mnemonic cause to poor performance on the double Y-maze task Taken together, these experiments demonstrate a synergistic disruption of working memory by acute co-administration of THC and MDMA.

Determination of the effectiveness of components of the herbal medicine Toki-Shakuyaku-San and fractions of Angelica acutiloba in improving the scopolamine-induced impairment of rat's spatial cognition in eight-armed radial maze test

The improving effects of various components of Toki-Shakuyaku-San (TSS) and fractions isolated from Angelica acutiloba Radix (Toki) on scopolamine-induced spatial memory impairment were investigated in eight-armed radial maze. The scopolamine-induced memory impairment was characterized by prominent increase of error choices in addition to decreased correct choices. Toki, Cnidium officinale Rhizoma (Senkyu), Poria cocos Hoelen (Bukuryo), Alisma orientale Rhizoma (Takusha), and Atractylodes lancea Rhizoma (Sojutsu) increased the correct choices, while only the Toki, Sojutsu, and Takusha decreased the error choices. No effect was produced by Paeonia lactiflora Radix (Shakuyaku). Investigation of effects of fractions isolated from Toki revealed that its activity mainly resided in the butanol layer and its contents of N-methyl-beta-carboline-3-carboxamide and amines. Moreover, the alkaloid, internal and external solutions (containing poly-, di-, and monosaccharides) obtained by dialysis with Visking cellophane tubing also improved the memory. However, no improving properties were detected for methanol and hexanol layers, L-(-)-tryptophan, L-arginine, L-(-)-lysine, and choline chloride. The results showed that the TSS components could improve the reference and working memory impaired by scopolamine. The improving effect of TSS is produced greatly by the Toki component, the activity of which was greatly produced by the fraction extracted by butanol.

Nucleus basalis magnocellularis electrical stimulation facilitates two-way active avoidance retention, in rats

We studied the effects of post-training intracranial electrical stimulation of the nucleus basalis magnocellularis on two-way active avoidance retention. After the acquisition, rats were stimulated for 20 min, and they were tested again after 24 h or 11 days. The treatment improved memory consolidation, especially in animals with a low initial learning ability. These facilitative effects could be attributed to an enhancement of cortical and/or amygdala activation, leading to an improvement in associative processes and/or cortical plasticity.

Bidirectional modulation of basal forebrain N-methyl-d-aspartate receptor function differentially affects visual attention but not visual discrimination performance

Basal forebrain neuronal circuits, specifically the corticopetal cholinergic system, mediate attentional abilities. The effects of infusions of N-methyl-D-aspartate (NMDA) and the competitive NMDA receptor antagonist DL-2-amino-5-phosphonovaleric acid (APV) into the basal forebrain were assessed in rats trained in an operant task designed to generate measures of sustained attention performance. Control animals were trained in a cued visual discrimination task devoid of explicit demands on attentional performance, but involving similar basic operant components as the sustained attention task. The effects of intrabasalis infusions of NMDA (1, 3 and 6nmol) and APV (3, 10 and 20nmol) were tested in separate groups of animals. Infusion of neither drug affected the animals' response accuracy in the cued visual discrimination task, indicating that performance in this task remains insufficient to activate basal forebrain NMDA receptors. Infusions of APV in sustained attention task-performing animals selectively decreased the animals' ability to detect visual signals, but spared their ability to reject non-signal events. Conversely, infusions of NMDA into the basal forebrain did not affect the animals' hit rate but increased their number of false alarms, i.e. "claims" for signals in non-signal trials. The concentrations of NMDA infused into the basal forebrain did not result in neurotoxic effects as demonstrated by a separate experiment, which indicated neurodegeneration following the infusion of 30 nmol NMDA as visualized by the Fluoro-Jade method.The effects of APV correspond with the attentional consequences of other manipulations known to impair the functions of cortical cholinergic input. Conversely, the effects of NMDA infusions agree with the hypothesis that overactivity of cortical cholinergic inputs mediates an abnormal overprocessing of the stimulus situation. Basal forebrain NMDA receptor manipulations assist in determining the role of this neuronal system in cognitive processes.

Deramciclane inhibits N-methyl-D-aspartate receptor function

Effects of the novel anxiolytic drug deramciclane on excitatory amino acid release and transmembrane Ca(2+) ion flux processes were compared in rat cerebrocortical homogenates containing resealed plasmalemma fragments and nerve endings. Deramciclane (10 microM) significantly inhibited [(3)H]D-aspartate release and transmembrane Ca(2+) flux to N-methyl-D-aspartate in the absence of Mg(2+). By contrast, inhibition of [(3)H]D-aspartate release and transmembrane Ca(2+) flux evoked by 0.1 mM (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate in the presence of Mg(2+) and 10 microM cyclothiazide by 10 microM deramciclane was not significant. In the presence of N-methyl-D-aspartate receptor antagonists, deramciclane (10 microM) did not inhibit [(3)H]D-aspartate release to N-methyl-D-aspartate. These results suggest an involvement of the inhibition of a presynaptic N-methyl-D-aspartate receptor in the anxiolytic properties of deramciclane.